Treatment of multiple sclerosis with masitinib
US8906357B2 · kind B2 · utility
0Cited by
0References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 2011 |
| Grant date | Dec 9, 2014 |
| Priority date | — |
| Expiry date | Apr 20, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a tyrosine kinase inhibitor or a mast cell inhibitor, and in particular masitinib or a pharmaceutically acceptable salt thereof, for the treatment of human multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.